Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: axial spondyloarthritis

FDA Approves 2 Upadacitinib Formulations for Children with pJIA & PsA

  |  

Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.

What’s New in Large Vessel Vasculitis

Philip Seo, MD, MHS  |  

The large vessel vasculitides were a major focus of the 21st International Vasculitis Workshop held in Barcelona in April. The biennial conference brings together specialists from multiple disciplines, including rheumatology, nephrology and immunology, to discuss cutting-edge vasculitis research. This article reviews important points regarding the pathogenesis, diagnosis and management of both giant cell arteritis and…

Can Reconsidering Our Relationship to Time Help Keep Us Present?

  |  

“I circled 30 minutes … but it feels more like five hours getting ready for work Monday to Friday and only 15 minutes in a hot bath on weekends,” my patient relayed to me. Greg (name changed, obviously) is an ambitious young professional who has axial spondyloarthritis. He’s also a really funny guy with a…

When a JAK Inhibitor Fails

  |  

What Are the Therapeutic Alternatives When a Janus Kinase Inhibitor Fails to Work? SAN DIEGO—Treatment alternatives after Janus kinase (JAK) inhibitor failure in real-life conditions were analyzed and presented at ACR Convergence 2023 by Pablo Francisco Muñoz Martínez, a rheumatologist at the Hospital Universitario y Politécnico La Fe, Sagunto, Spain.1 JAK inhibitors are newer, targeted…

The Heterogeneity of Psoriatic Arthritis

David S. Pisetsky, MD, PhD  |  

SAN DIEGO—Differences between psoriatic arthritis and rheumatoid arthritis highlight the need for the development of imaging modalities, laboratory tests and other biomarkers that are explored and validated specifically for PsA to advance the goal of personalized or precision medicine. In this article, expert David S. Pisetsky, MD, PhD, explores the top research in psoriatic arthritis presented at ACR Convergence 2023.

Pearls & Pitfalls in Diagnosing nr-axSpA

  |  

This session (12S114) at ACR Convergence 2023 will review the diagnostic approach to nonradiographic axial spondyloarthritis, with an emphasis on the role of imaging and recognition of its mimics. For your review—or a preview if you plan to catch the session on demand—our article will capture the highlights from Lianne Gensler, MD, Mark Hwang, MD,…

The Effect of Upadacitinib on Bone Erosion in Patients with RA

  |  

Ho et al. found that upadacitinib may impede the progression of bone erosion in patients with RA. Additionally, bone scans of patients with limited exposure to conventional synthetic disease-modifying antirheumatic drugs showed bone erosion regression, which may result from upadacitinib’s inhibition of Janus kinase 1.